Nasopharyngeal carcinoma: nationwide trends in subtype-specific incidence and survival over 3 decades in a non-endemic area.

"Declarations Conflict of interestS.F.O. reports a research contract with Merck KGaA, consultancy fees from Bristoll Myers Squibb, Genmab and Merck KGaA (paid to the institution) and unpaid consultancy for ALX Oncology. B.v.d.V. reports honoraria received by the University Medical Center Groningen for expertise or scientific advisory board/consultancy from Visiopharm, Philips, MSD/Merck, Daiichi-Sankyo/AstraZenica; Speaker’s fee from Visiopharm, Diaceutics, MSD/Merck. B.E.C.P. reports research grants, consultancy fees and honoraria from Olympus EU. J.A.L. reports consultancy fees from IBA and RaySearch laboratories, and collaborative research contracts with IBA, RaySearch laboratories, Elekta, Mirada and Siemens. All other authors have no potential conflicts of interest. Ethical approvalSince the data were anonymized, ethics approval was not required. Consent to participateNot applicable. Consent to publishNot applicable. Conflict of interest S.F.O. reports a research contract with Merck KGaA, consultancy fees from Bristoll Myers Squibb, Genmab and Merck KGaA (paid to the institution) and unpaid consultancy for ALX Oncology. B.v.d.V. reports honoraria received by the University Medical Center Groningen for expertise or scientific advisory board/consultancy from Visiopharm, Philips, MSD/Merck, Daiichi-Sankyo/AstraZenica; Speaker’s fee from Visiopharm, Diaceutics, MSD/Merck. B.E.C.P. reports research grants, consultancy fees and honoraria from Olympus EU. J.A.L. reports consultancy fees from IBA and RaySearch laboratories, and collaborative research contracts with IBA, RaySearch laboratories, Elekta, Mirada and Siemens. All other authors have no potential conflicts of interest."

"Funding This research did not receive funding from agencies in the public, commercial, or not-for-profit sectors."